Daiichi Sankyo

Debbie's Dream Foundation: Curing Stomach Cancer Celebrates a Year of Impactful Programs and Community Support in 2023

Retrieved on: 
Wednesday, January 3, 2024
Veteran, Stomach, Travel, Amgen, ASCO, Caregiver, DDF, Daiichi Sankyo, Research, Zymeworks, DSI, Copper, Stomach cancer, Federation, Genetics, BMS, United Way, Mind, Patient, Medicine, Bristol Myers Squibb, Club, Pharmaceutical industry

FORT LAUDERDALE, Fla., Jan. 3, 2024 /PRNewswire/ -- Debbie's Dream Foundation: Curing Stomach Cancer (DDF) proudly wraps up an impactful year, delivering crucial resources and support to the stomach cancer community, thanks to the unwavering commitment of 2023 industry partners. The support from generous sponsors has allowed DDF to continue vital programs and initiate new endeavors. This year, DDF worked closely with sponsors such as Amgen, Arcus, Astellas, Bristol Myers Squibb (BMS), Daiichi Sankyo (DSI), Genentech, Lilly Oncology, Merck, Taiho Oncology, and Zymeworks, whose dedication has been instrumental in advancing various programs, ensuring DDF's continued service to patients, their families, and caregivers.

Key Points: 
  • FORT LAUDERDALE, Fla., Jan. 3, 2024 /PRNewswire/ -- Debbie's Dream Foundation: Curing Stomach Cancer (DDF) proudly wraps up an impactful year, delivering crucial resources and support to the stomach cancer community, thanks to the unwavering commitment of 2023 industry partners.
  • The support from generous sponsors has allowed DDF to continue vital programs and initiate new endeavors.
  • At the top of the year, DDF hosted its Inaugural Patient Advocate Retreat during its 11th Annual Stomach Cancer Capitol Hill Advocacy Day in Washington, D.C.
  • For the 2023 Symposia series, DDF collaborated with Moffitt Cancer Center in Tampa, Florida, to host a Stomach Cancer Educational Symposium.

INmune Bio Inc. Demonstrates that INB03 Enhances the Uptake of Trastuzumab Deruxtecan in HER2+ Breast Cancer with MUC4 Expression in Poster Presented at San Antonio Breast Cancer Symposium

Retrieved on: 
Wednesday, November 29, 2023
Immunotherapy, Daiichi Sankyo, TNF, Neoplasm, Tumor microenvironment, TME, HER2, Woman, Breast cancer, TAM, Disease, Interferon gamma, MUC4, Poster, ADC, Vaccine

Boca Raton, Florida, Nov. 29, 2023 (GLOBE NEWSWIRE) --  INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, is presenting data on the use of INB03, a dominant-negative TNF inhibitor of soluble TNF (sTNF) in the treatment of high-risk MUC4 expressing HER2. Roxana Schillaci, Ph.D., of Instituto de Biología y Medicina Experimental in Buenos Aries, Argentina, will present her work at the 46th annual San Antonio Breast Cancer Symposium, which runs from December 5 to 9.

Key Points: 
  • Roxana Schillaci, Ph.D., of Instituto de Biología y Medicina Experimental in Buenos Aries, Argentina, will present her work at the 46th annual San Antonio Breast Cancer Symposium, which runs from December 5 to 9.
  • “This work demonstrates another way that MUC4 expression causes resistance to HER2-targeted immunotherapy in women with resistant breast cancer," said Dr. Schillaci, who is also associated with CONICET and is senior author of this work.
  • INB03 decreases MUC4 expression on the surface of the breast cancer cells increasing the ability of the antibody to bind to the HER2 target on the cancer cell.
  • Resistance to trastuzumab immunotherapy can be predicted prospectively based on simple immunohistochemistry stains detecting tumor expression of MUC4.

Pyxis Oncology Announces Appointment of Ken Kobayashi, M.D., F.A.C.P as Chief Medical Officer

Retrieved on: 
Tuesday, November 28, 2023
AB, Pfizer, National Cancer Institute, Food, AstraZeneca, Daiichi Sankyo, Spacecraft, CMO, Janssen, File, Drug, Novartis, Shirin David, Feinberg School of Medicine, Cancer, Patient, Therapy, ADC, Senior, Pharmaceutical industry

BOSTON, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company focused on developing next-generation therapeutics to target difficult-to-treat cancers, today announced the appointment of Ken Kobayashi, M.D., F.A.C.P, as Chief Medical Officer (CMO), effective November 27, 2023.

Key Points: 
  • BOSTON, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company focused on developing next-generation therapeutics to target difficult-to-treat cancers, today announced the appointment of Ken Kobayashi, M.D., F.A.C.P, as Chief Medical Officer (CMO), effective November 27, 2023.
  • Dr. Kobayashi brings extensive leadership experience in oncology clinical development and regulatory affairs.
  • As CMO, Dr. Kobayashi will lead the Company’s clinical and regulatory operations, drive strategic growth, and play a key role in advancing Pyxis Oncology’s clinical pipeline.
  • “I am thrilled to welcome Ken to the Pyxis Oncology team, and I look forward to working closely with him to advance our clinical programs,” said Lara S. Sullivan, M.D., President and Chief Executive Officer of Pyxis Oncology.

Patritumab Deruxtecan Granted Priority Review in the U.S. for Certain Patients with Previously Treated Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer

Retrieved on: 
Friday, December 22, 2023
Biotechnology, Pharmaceutical, Health, Oncology, MSD, Senior, Food, Leukopenia, Priority review, Hypokalemia, Daiichi Sankyo, FDA, Breakthrough therapy, PDUFA, EGFR, ILD, Anemia, Fatigue, HER3, Neutropenia, MD, Biologics license application, Recurrence, Patritumab, Weakness, Thrombocytopenia, Merck & Co., DXD, Patient, Safety, Medicine, MRK, ADC, NSCLC, BLA, Pharmaceutical industry

The Prescription Drug User Fee Act (PDUFA) date, the FDA action date for their regulatory decision, is June 26, 2024.

Key Points: 
  • The Prescription Drug User Fee Act (PDUFA) date, the FDA action date for their regulatory decision, is June 26, 2024.
  • The Priority Review follows receipt of Breakthrough Therapy Designation granted by the FDA in December 2021.
  • RTOR allows the FDA to review components of an application before submission of the complete application.
  • Twelve patients (5.3%) had confirmed treatment-related interstitial lung disease (ILD) as determined by an independent adjudication committee.

Hatch BioFund Announces New Partnership with Brandywine Realty Trust

Retrieved on: 
Wednesday, December 20, 2023
Biotechnology, Technology, Professional Services, Health, General Health, Pharmaceutical, Other Science, Other Technology, Research, Science, Finance, Partnership, COVID-19, ARD International Music Competition, Nobel, Daiichi Sankyo, FDA, COVID-19 vaccine, Hepatitis, PABC, Hepatitis B, Brandywine Realty Trust, Business development, Hepatitis B Foundation, Growth, Pharmaceutical industry

Hatch BioFund Management LLC (“Hatch BioFund”), an early- stage life sciences venture capital firm headquartered in the Philadelphia region, and Brandywine Realty Trust (“Brandywine”), one of the largest, publicly traded, full-service, integrated real estate companies in the United States, announced today a new partnership to support the advancement of life sciences companies in Greater Philadelphia.

Key Points: 
  • Hatch BioFund Management LLC (“Hatch BioFund”), an early- stage life sciences venture capital firm headquartered in the Philadelphia region, and Brandywine Realty Trust (“Brandywine”), one of the largest, publicly traded, full-service, integrated real estate companies in the United States, announced today a new partnership to support the advancement of life sciences companies in Greater Philadelphia.
  • “We are proud that Brandywine selected Hatch BioFund as its investment partner,” said Lorenzo Pellegrini, Ph.D., managing partner of Hatch BioFund.
  • “Brandywine’s platform will be invaluable in our team’s effort to support the growth of exceptional life science entrepreneurs in the Greater Philadelphia region.
  • Additionally, Philadelphia was recently named one of five regions in the country to receive a biotechnology hub designation from the Biden administration.

Metastatic Castration-Resistant Prostate Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 7.5% During the Study Period (2019-2032), Estimates DelveInsight

Retrieved on: 
Wednesday, December 20, 2023
GT0918, Niraparib, Phase, Ipsen, CRPC, Prognosis, Daiichi Sankyo, PSMA, BRCA, FDA, Spacecraft, Gesellschaft mit beschränkter Haftung, DNA, EU4, Cancer, Novartis, ICIS, Abiraterone acetate, Ageing, Urination, PSA, Metastasis, CYP17, Survival rate, Pain, Prevalence, Bristol Myers Squibb, Prednisone, Janssen Pharmaceuticals, Testosterone, PARP, Rucaparib, Urine, Neoplasm, Urethra, Johnson & Johnson, AstraZeneca, Docetaxel, STEAP1, Bone pain, AMG, Blood, ADT, LAS, Patient, Prostate-specific antigen, Astellas Pharma, HRR, Amgen, Prostate cancer, Swelling, Eli Lilly and Company, Hypoesthesia, Science, Growth, Merck & Co., Pressure, Pharmaceutical industry

LAS VEGAS, Dec. 20, 2023 /PRNewswire/ -- DelveInsight's Metastatic Castration-Resistant Prostate Cancer Market Insights report includes a comprehensive understanding of current treatment practices, mCRPC emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan].

Key Points: 
  • As per DelveInsight analysis, the total metastatic castration-resistant prostate cancer market size in the 7MM was estimated to be nearly USD 6.4 billion in 2022, which is expected to show positive growth by 2032.
  • As per DelveInsight estimates, in 2022, total diagnosed prevalent cases of mCRPC were around 127K in the 7MM.
  • However, mCRPC remains a lethal diagnosis and more effective therapeutic approaches against mCRPC are necessary to improve clinical outcomes further.
  • The estimated five-year survival rate for men with metastatic prostate cancer is approximately 30%, in stark contrast to the 100% survival rate for those with localized prostate cancer.

Metastatic Castration-Resistant Prostate Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 7.5% During the Study Period (2019-2032), Estimates DelveInsight

Retrieved on: 
Wednesday, December 20, 2023
GT0918, Niraparib, Phase, Ipsen, CRPC, Prognosis, Daiichi Sankyo, PSMA, BRCA, FDA, Spacecraft, Gesellschaft mit beschränkter Haftung, DNA, EU4, Cancer, Novartis, ICIS, Abiraterone acetate, Ageing, Urination, PSA, Metastasis, CYP17, Survival rate, Pain, Prevalence, Bristol Myers Squibb, Prednisone, Janssen Pharmaceuticals, Testosterone, PARP, Rucaparib, Urine, Neoplasm, Urethra, Johnson & Johnson, AstraZeneca, Docetaxel, STEAP1, Bone pain, AMG, Blood, ADT, LAS, Patient, Prostate-specific antigen, Astellas Pharma, HRR, Amgen, Prostate cancer, Swelling, Eli Lilly and Company, Hypoesthesia, Science, Growth, Merck & Co., Pressure, Pharmaceutical industry

LAS VEGAS, Dec. 20, 2023 /PRNewswire/ -- DelveInsight's Metastatic Castration-Resistant Prostate Cancer Market Insights report includes a comprehensive understanding of current treatment practices, mCRPC emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan].

Key Points: 
  • As per DelveInsight analysis, the total metastatic castration-resistant prostate cancer market size in the 7MM was estimated to be nearly USD 6.4 billion in 2022, which is expected to show positive growth by 2032.
  • As per DelveInsight estimates, in 2022, total diagnosed prevalent cases of mCRPC were around 127K in the 7MM.
  • However, mCRPC remains a lethal diagnosis and more effective therapeutic approaches against mCRPC are necessary to improve clinical outcomes further.
  • The estimated five-year survival rate for men with metastatic prostate cancer is approximately 30%, in stark contrast to the 100% survival rate for those with localized prostate cancer.

BioMarin Announces Governance Enhancements and Value Creation Initiatives

Retrieved on: 
Wednesday, December 20, 2023
Adverum Biotechnologies, University, Ambit Biosciences, Daiichi Sankyo, Hill-Rom, Indiana University, Harvard Law School, Baxter, Acceleration, Strategy, Palmer, Pfizer, Biotechnology Innovation Organization, Invacare, Eli Lilly, Hospira, Pediatrics, Chairperson, The Nature Conservancy, Genzyme, American Cancer Society, Therapy, Goldman Sachs, M.B.A, BMRN, ImmunoGen, DSM-IV codes, Shire (pharmaceutical company), IPO, Patient, Proteostasis, BioMarin Pharmaceutical, Corporate development, Dentsply Sirona, Senior, Syneos Health, Iovance Biotherapeutics, Sclerosis, Acquisition, SAN, CIO, Eli Lilly and Company, Interim, Bristol Myers Squibb, Information technology, Management

SAN RAFAEL, Calif., Dec. 20, 2023 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), a global biotechnology company dedicated to transforming lives through genetic discovery, today announced several initiatives to enhance corporate governance and long-term shareholder value creation.

Key Points: 
  • SAN RAFAEL, Calif., Dec. 20, 2023 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), a global biotechnology company dedicated to transforming lives through genetic discovery, today announced several initiatives to enhance corporate governance and long-term shareholder value creation.
  • "Today's announcements will strengthen our ability to drive better outcomes for patients with genetic diseases and deliver value to all stakeholders.
  • BioMarin plays a pivotal role in the treatment of genetic diseases thanks to its globally leading rare-disease portfolio.
  • We believe the changes announced today put BioMarin in the best position to realize its full potential, and we support Alexander Hardy as the right leader for this chapter of BioMarin's value creation story.

Two Phase 3 Trials of Datopotamab Deruxtecan Plus Durvalumab Initiated in Patients Across Two Breast Cancer Subtypes

Retrieved on: 
Monday, December 18, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Durvalumab, PD-L1, Breast, Safety, Research, AstraZeneca, Neoadjuvant therapy, ADC, Breast cancer, Patient, Neoplasm, TSE, DXD, Prognosis, HER2, MD, Survival, HR, Recurrence, Immunotherapy, CPS, TNBC, Pharmaceutical industry, Medical imaging, Daiichi Sankyo

Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) being jointly developed by Daiichi Sankyo and AstraZeneca.

Key Points: 
  • Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) being jointly developed by Daiichi Sankyo and AstraZeneca.
  • TROPION-Breast04 is evaluating neoadjuvant datopotamab deruxtecan plus durvalumab followed by adjuvant durvalumab with or without chemotherapy in patients with stage II-III triple negative breast cancer (TNBC) or hormone receptor (HR) low, HER2 low or negative breast cancer.
  • TROPION-Breast05 is evaluating datopotamab deruxtecan alone and in combination with durvalumab in patients with locally recurrent inoperable or metastatic TNBC whose tumors express PD-L1 (CPS ≥ 10).
  • TROPION-Breast03 is evaluating datopotamab deruxtecan with and without durvalumab versus investigator’s choice of therapy in patients with stage I to III TNBC with residual disease after neoadjuvant therapy.

Depixus Announces Strategic Collaboration With Daiichi Sankyo to Use MAGNA™ Technology to Accelerate RNA-targeted Drug Discovery

Retrieved on: 
Tuesday, December 12, 2023
Health, Genetics, Research, Pharmaceutical, Science, Biotechnology, Interactome, Laboratory, Kinetics, Protein, Therapy, Daiichi Sankyo, DNA, Drug discovery, RNA, Proteolysis targeting chimera, Pharmaceutical industry, Vaccine

Interactomics pioneer Depixus has entered a collaboration with Daiichi Sankyo to use their novel MAGNA™ technology to accelerate the Japanese healthcare leader’s RNA-targeted drug discovery program.

Key Points: 
  • Interactomics pioneer Depixus has entered a collaboration with Daiichi Sankyo to use their novel MAGNA™ technology to accelerate the Japanese healthcare leader’s RNA-targeted drug discovery program.
  • Based on magnetic force spectroscopy, MAGNA is a unique technology that enables high-throughput analysis of dynamic biomolecular interactions in real time with single-molecule resolution.
  • The team at Daiichi Sankyo will use MAGNA to explore the interactions of lead molecules with a number of undisclosed RNA targets.
  • Gordon Hamilton, M.D., CEO of Depixus, said, “The world of RNA-targeted therapeutics has huge potential, yet is largely unexplored.